We examined the hypothesis that atrial natriuretic factor (ANF), a substance with known vasorelaxant activities, shares with other vasodilators the property of inhibiting platelet function. Aggregation of citrated platelet-rich plasma (PRP) from 23 healthy volunteers induced by ADP, adrenaline, arachidonic acid, collagen, γ-thrombin, the endoperoxide analogue U-44069, serotonin, the calcium ionophore A-23187 or platelet aggregating factor was measured after incubation of PRP with ANF for 3 minutes at concentrations of 4 x 10-9, 4 x 10-8 and 4 x 10-7 M or vehicle as control. ANF decreased ADP-induced aggregation significantly (P < 0.02), but only at the highest concentration used and to a minor extent (control: 73.6 ± 11.2%; after ANF 4 x 10-7 M: 60.0 ± 17.1%, mean ± S.D., n = 39) by a selective inhibitory effect on the secondary wave; neither aggregation by all other agents tested nor thromboxane B2 generation induced by ADP and adrenaline was altered by incubation with ANF. Although ANF thus has detectable effects on ADP-induced platelet aggregation in vitro, these data suggest that ANF is unlikely to be a physiologically significant modulator of platelet function.
Effects of atrial natriuretic factor on human platelet function / Raffaele De, Caterina; Volpe, Massimo; Steven A., Atlas; Babette B., Weksler. - In: LIFE SCIENCES. - ISSN 0024-3205. - 37:15(1985), pp. 1395-1402. [10.1016/0024-3205(85)90078-5]
Effects of atrial natriuretic factor on human platelet function
VOLPE, Massimo;
1985
Abstract
We examined the hypothesis that atrial natriuretic factor (ANF), a substance with known vasorelaxant activities, shares with other vasodilators the property of inhibiting platelet function. Aggregation of citrated platelet-rich plasma (PRP) from 23 healthy volunteers induced by ADP, adrenaline, arachidonic acid, collagen, γ-thrombin, the endoperoxide analogue U-44069, serotonin, the calcium ionophore A-23187 or platelet aggregating factor was measured after incubation of PRP with ANF for 3 minutes at concentrations of 4 x 10-9, 4 x 10-8 and 4 x 10-7 M or vehicle as control. ANF decreased ADP-induced aggregation significantly (P < 0.02), but only at the highest concentration used and to a minor extent (control: 73.6 ± 11.2%; after ANF 4 x 10-7 M: 60.0 ± 17.1%, mean ± S.D., n = 39) by a selective inhibitory effect on the secondary wave; neither aggregation by all other agents tested nor thromboxane B2 generation induced by ADP and adrenaline was altered by incubation with ANF. Although ANF thus has detectable effects on ADP-induced platelet aggregation in vitro, these data suggest that ANF is unlikely to be a physiologically significant modulator of platelet function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.